Mum

Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis

One Groundbreaking Study Showed 11 Percent Fewer RA PatientsReported Job Loss When Treated With HUMIRA Combination TherapyCompared to Methotrexate Alone BARCELONA, Spain, June 15, 2007 /PRNewswire-FirstCall/ --Rheumatoid arthritis (RA) is one of the most common causes ofdisability in the Western world. New data released today show thatrheumatoid arthritis (RA) patients treated with Abbott...

GlaxoSmithKline and Genmab Present Positive Phase II Results With ofatumumab in Patients With Rheumatoid Arthritis (RA)

New Data to be Presented at the European League Against Rheumatism(EULAR) Congress Demonstrates the Potential Benefit of ofatumumabin Patients With Rheumatoid Arthritis LONDON, England; PHILADELPHIA, Pennsylvania and COPENHAGEN,Denmark, June 15, 2007 /PRNewswire-FirstCall/ -- GlaxoSmithKline(GSK) and Genmab A/S (CSE: GEN) announced today positive primaryefficacy data (evaluated at 24 Week...

Anti-TNF Golimumab Continues to Show Promise in Phase II Rheumatoid Arthritis Study

Golimumab Demonstrated Sustained Improvement in Signs andSymptoms Of Moderate to Severe Rheumatoid Arthritis With One-Thirdof Patients Achieving Disease Remission at One-YearMark BARCELONA, Spain, 14 June 2007 – One-year data show nearly75 percent of patients with moderate to severe rheumatoid arthritis(RA) receiving golimumab (CNTO 148) and methotrexate (MTX)experienced a...

Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab

Clinical Phase I and II data presented at American Society ofClinical Oncology (ASCO) 2007 Annual Meeting CHICAGO, June 05, 2007 /PRNewswire-FirstCall/ -- Medarex, Inc.and Bristol-Myers Squibb Company today presented results frommultiple clinical studies of ipilimumab (MDX-010), aninvestigational immunotherapy, for patients with advanced melanoma.The results demonstrated an anti-tumor res...

New Analysis of Data Shows Treatment With Abbott's Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohn's Disease

HUMIRA Data Showed 57 Percent Reduction in Risk of Hospitalizationfrom Crohn's Disease vs. Placebo at One Year ABBOTT PARK, Ill., May 22, 2007 /PRNewswire-FirstCall/ -- Abbotttoday announced results from a post-hoc analysis of a pivotal studypresented at the Digestive Disease Week annual meeting inWashington, D.C. showing patients with moderate to severely activeCrohn's disease treated wi...

New Data on Genmab and GlaxoSmithKline's Ofatumumab: Phase II Study in Rheumatoid Arthritis to be Presented at EULAR

COPENHAGEN, Denmark; April 25, 2007 - Genmab A/S (CSE: GEN)announced today that the results of a Phase II study withofatumumab (HuMax-CD20™) in patients with rheumatoidarthritis (RA) have been accepted for oral presentation at the 2007Annual European Congress of Rheumatology (EULAR). The oralpresentation, which will include new results from the double-blind,placebo controlled Phase...